logo
logo
BLFS stock ticker logo

BioLife Solutions, Inc.

NASDAQ•BLFS
CEO: Mr. Roderick de Greef
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1989-11-22
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Contact Information
3303 Monte Villa Parkway, Suite 310, Bothell, WA, 98021, United States
425-402-1400
www.biolifesolutions.com
Market Cap
$971.15M
P/E (TTM)
-79.4
57.7
Dividend Yield
--
52W High
$29.62
52W Low
$19.10
52W Range
10%
Rank62Top 92.6%
1.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$18.79M+0.00%
4-Quarter Trend

EPS

$0.08+0.00%
4-Quarter Trend

FCF

$2.82M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Growth Strong Total revenue reached $96.2M in 2025, marking a strong 29% increase over 2024 results.
Net Loss Significantly Narrowed Net loss narrowed substantially to $(4.6M) in 2025, a major improvement from the $(20.2M) loss reported in 2024.
PanTHERA Acquisition Closed Completed PanTHERA acquisition in April 2025, immediately recognizing $15.5M in IPR&D expense.
Cash Position Strengthened Total cash and available-for-sale securities grew 14% to $120.2M by year-end 2025, supporting liquidity.

Risk Factors

Customer Concentration Exposure Revenue heavily reliant on few customers; top three accounted for 29% of total 2025 revenue.
Operating Expenses Surge Total operating expenses surged 44% in 2025, primarily driven by the $15.5M IPR&D charge.
Supply Chain Dependencies Dependent on suppliers and third-party manufacturers; supply chain disruptions pose a material operational risk.
Internal Control Weaknesses Historical material weakness in internal controls over financial reporting was identified for 2024, though remediated.

Outlook

R&D Investment Increased Research and development spending increased 59% in 2025, signaling strong focus on product innovation pipeline.
CGT Market Strategy Focus Strategy centers on commercializing differentiated, best-in-class products for the rapidly expanding cell and gene therapy market.
Leveraging Partner Relationships Plan to leverage existing relationships with leading CGT companies for cross-selling portfolio offerings effectively.
No Near-Term Dividends Company retains all earnings for expansion and capital needs; no cash dividends are anticipated in the foreseeable future.

Peer Comparison

Revenue (TTM)

NEOG stock ticker logoNEOG
$880.32M
-3.7%
NVCR stock ticker logoNVCR
$655.35M
+8.3%
AZTA stock ticker logoAZTA
$595.19M
-8.4%

Gross Margin (Latest Quarter)

HROW stock ticker logoHROW
79.3%
-0.3pp
NVCR stock ticker logoNVCR
75.8%
-3.9pp
STAA stock ticker logoSTAA
75.7%
+17.6pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
NEOG$2.37B-3.9-26.9%23.6%
ESTA$2.07B-41.3-201.8%0.8%
ATRC$1.57B-131.8-2.4%13.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-7.8%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow

Deep Research

Next earnings:May 6, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data